DeuterOncology
PrivateLast Round
Grant
Apr 7, 2023
Total Funding Raised
$12.72M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
DeuterOncology is a biotechnology company developing a deuterated MET kinase inhibitor as a targeted therapy for MET driven diseases, such as lung cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DeuterOncology Comparables
Compare DeuterOncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novartis | 76% | |
| HUTCHMED (China) Limited | 74% | |
| Merck | 73% |
DeuterOncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 7, 2023 | ||||
| Series A | Jan 19, 2023 | ||||
| Series A | Jan 19, 2023 | ||||
| Seed | Feb 24, 2021 |
Key People
Founding team and executive leadership
DeuterOncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Public service of Wallonia | Grant |
| Newton Biocapital | Series A, Seed |
| Noshaq | Series A |
| Financière Spin-off Luxembourgeoise | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 86% MoM.
- Dec 8, 2025
Monthly visitors increased 677% MoM.
DeuterOncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about DeuterOncology's valuation, stock price, and market status.
Is DeuterOncology a public or private company?
DeuterOncology is a private company.
What is the current stock price of DeuterOncology?
DeuterOncology is a private company with no public stock price. No recent secondary market data is available.
How much is DeuterOncology worth (valuation)?
Valuation information for DeuterOncology is not publicly available.
Can I buy DeuterOncology stock?
DeuterOncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was DeuterOncology's last funding round?
DeuterOncology's most recent funding round was Grant on April 7, 2023.
Who are the main investors in DeuterOncology?
Key investors in DeuterOncology include Newton Biocapital.
Will DeuterOncology IPO soon?
No public IPO plans have been announced for DeuterOncology.
How can I track DeuterOncology secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DeuterOncology's secondary market activity and sign up for updates.